Gene · 7913
NIH grants1,044
NIH grants whose papers are about the gene, through NIH's grant-paper links.
101 to 120 of 1,044
Download this page as JSON| Grant | Title | DEK papers | Newest fiscal year |
|---|---|---|---|
| R01AR041398 | Novel Molecular Biomarkers of Bone Microarchitecture | 1 | 2025 |
| R01AR079223 | Stable therapy in Pompe disease through genome editing | 1 | 2025 |
| R01CA096512 | Cell model for KSHV infection and genetic manipulation | 1 | 2025 |
| R01CA107469 | Role of EZH2 in Breast Cancer Progression | 1 | 2025 |
| R01CA124332 | Regulation of KSHV replication by N6-methyladenosine (m6A) | 1 | 2025 |
| R01CA132878 | Post-translational Modifications in DNA Damage Response: a Structural Perspective | 1 | 2025 |
| R01CA137124 | Production and progression of premalignant retinoblastoma lesions. | 1 | 2025 |
| R01CA152108 | Molecular and Cellular Mechanisms of Chronic Myelomonocytic Leukemia (CMML) | 1 | 2025 |
| R01CA198279 | Shaping DNA Damage Response Networks Via Histone H2A Variants | 1 | 2025 |
| R01CA207209 | Inhibition of the ALT pathway by interfering with Poly-ADP-Ribose metabolism | 1 | 2025 |
| R01CA218285 | Immuno and Epigenetics of Hematopoietic Cell Transplantation | 1 | 2025 |
| R01CA250412 | Impact of Circulating Myeloid Cell Clusters on Anti-Tumor Immunity | 1 | 2025 |
| R01CA260857 | Multiplexed time domain fluorescence tomography of tumor biomarkers during immunotherapy | 1 | 2025 |
| R01CA260872 | A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients | 1 | 2025 |
| R01CA262316 | Co-Regulation of Alternative Lengthening of Telomeres and Chromatin Dynamics in ATRX-DAXX deficient cancer cells | 1 | 2025 |
| R01DE025208 | KSHV Latent Infection Replication | 1 | 2025 |
| R01DK069710 | The Role of Nuclear PARPs in Signal-Regulated Transcription | 1 | 2025 |
| R01DK117850 | Systems Genetics Dissection of Non-alcoholic Steatohepatitis | 1 | 2025 |
| R01ES007061 | Mechanisms of DNA Double-strand Break End Resection and Repair Pathway Choice | 1 | 2025 |
| R01ES007331 | Mechanisms of Methylmercury Induced Neuronal Toxicity | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/7913/grants?page=6